34 results about "Bone marrow sample" patented technology

The present application is directed to the separation of—a solid fraction from a fluid sample particularly a therapeutic cellular fraction from a biological sample such as a bone marrow sample by a porous filter (2) which separates a filtration unit (1) into an upper pre-filtration chamber (3) into which a fluid sample (4) requiring cell separation is introduced and a lower post-filtration chamber (5) into which a fluid (6) capable of transmitting an acoustic standing wave is introduced. An acoustic element (8) is coupled to a substrate (7) which is located within and at the bottom of the lower chamber (5) and which resonates in response to the acoustic generating element (8) and generates a standing wave through the two fluid phases and the filter to agitate the sample (4). Simultaneously, a cyclic process of vacuum draw (9). causes movement of the sample (4) downwards through the filter (2). Vacuum pressure, fluid flow rate and frequency of vibration are controlled from a remote unit housing appropriate pumps and valves.

The present application is directed to the separation of—a solid fraction from a fluid sample particularly a therapeutic cellular fraction from a biological sample such as a bone marrow sample by a porous filter (2) which separates a filtration unit (1) into an upper pre-filtration chamber (3) into which a fluid sample (4) requiring cell separation is introduced and a lower post-filtration chamber (5) into which a fluid (6) capable of transmitting an acoustic standing wave is introduced. An acoustic element (8) is coupled to a substrate (7) which is located within and at the bottom of the lower chamber (5) and which resonates in response to the acoustic generating element (8) and generates a standing wave through the two fluid phases and the filter to agitate the sample (4). Simultaneously, a cyclic process of vacuum draw (9). causes movement of the sample (4) downwards through the filter (2). Vacuum pressure, fluid flow rate and frequency of vibration are controlled from a remote unit housing appropriate pumps and valves.

A system and apparatuses or devices capable of automatically performing processes of cell treatment preparatory to flow cytometry and similar cytological studies in a fully automated and streamlined manner are provided. The system and apparatuses or devices are adapted for preparation and (pre)processing of cell samples, e.g., blood and / or bone marrow samples.

This disclosure describes systems, methods, and apparatuses for forming concentrates of platelet-rich plasma or bone marrow cells having user-defined concentrations, concentration ranges, and / or volumes. Whole blood or bone marrow samples can be passed through one or two separation operations in which platelets or bone marrow cells are separated from red blood cells and concentrated in a plasma. During this separation and concentrating, a total number of platelets or bone marrow cells or a concentration of either is determined and then used to ascertain what volumes and concentrations need be mixed in order to produce a platelet-rich plasma concentrate or a bone marrow-rich plasma concentrate having a target concentration and / or volume.

The present invention discloses using SPR technology to detect MM related genomic imbalances in bone marrow samples. An efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of DNA markers used for the identification of MM related genomic imbalances in bone marrow samples is also disclosed.

The present invention relates to the field of cancer therapy. More specifically, the present invention provides methods and compositions useful for augmenting anti-tumor immunity. In one embodiment, a method for treating or preventing post-allogeneic transplant relapse in a subject who has received post-transplant cyclophosphamide treatment comprises the steps of (a) obtaining a bone marrow sample from the subject; (b) expanding the marrow infiltrating lymphocytes (MILs) present in the sample; and (c) administering the MILs to the subject. In a specific embodiment, the method significantly reduces the likelihood of developing GVHD.

The invention relates to an acute myeloid leukemia miRNA and transcription factor model and a construction method and application thereof. The construction method includes: acquiring differential expression miRNA and different expression transcription factors of marrow samples of acute myeloid leukemia patients and a healthy contrast group, constructing a miRNA-transcription factor regulatory network model to obtain core miRNA and core transcription factors, and the like. The constructed miRNA and transcription factor model can be used for construction of diagnosis probes, chips or reagents, equipment and the like to provide intermediate result information or reference information for diagnosis of the acute myeloid leukemia patients. By the acute myeloid leukemia miRNA and transcription factor model, microRNA mediated network regulation contents are enriched, and an action mechanism of a microRNA and transcription factor mediated regulation network in AML (acute myeloid leukemia) is revealed. Research results lay the foundation for development of anti-leukemia medicines or biological products, and high application value is achieved.

The invention discloses a hematology bone marrow puncture extracting device. The device comprises an outer tube body and a base, the outer tube body is internally and fixedly connected with an inner tube body, a first piston is slidably connected between the inner surface of the outer tube body and the outer surface of the inner tube body, the top of the first piston is fixedly connected with a pushing tube, the pushing sleeves the inner tube body, the top of the pushing tube extends to the exterior of the outer tube body, the top of the pushing tube is fixedly connected with a first pushing plate, and the hematology bone marrow puncture extracting device relates to the technical field of medical instruments. The hematology bone marrow puncture extracting device has the advantages that theouter tube body and the inner tube body are cooperatively used together with an inner needle head and an outer needle head, the outer tube body is used for storing anaesthetic, the inner tube body isused for storing bone marrow samples, so that the extracted bone marrow does not contain the anaesthetic, the quality of bone marrow is not influenced, a first piston and a second piston can be pushed to slide by the pushing tube and a crossed pushing rod respectively to be used for anaesthetic injection and bone marrow extraction, the pushing tube and the crossed pushing rod do not interfere with each other, and the use is convenient.

The invention relates to the field of leukaemia drug resistance and discloses application of an ALC1 inhibitor to preparation of a leukaemia drug resistance reversing agent and application of an ALC1 gene to preparation of a drug-resistant leukaemia diagnosing reagent. The expression of the ALC1 gene in a peripheral blood sample or a bone marrow sample of a patient is detected; and based on a characteristic that the high expression of the gene is related to the increase of the resistance of a cell to chemotherapeutic medicines, sensitive chemotherapeutic agents can be screened. The invention further discloses an application of the ALC1 gene to preparation of the leukaemia drug resistance reversing agent. By inhibiting the expression of the ALC1 gene, the drug resistance of the cell can be reversed, the sensitivity of a leukemia cell to the medicine can be improved, and the cell inhibiting effects and the apoptosis promoting effects of various chemotherapeutic medicines can be improved, so that the ALC1 inhibitor can be applied to the preparation of acute and chronic leukaemia multidrug resistance reversing agents and a new method for treating the drug-resistant leukaemia is provided.

The method of the present invention can rapidly identify with expected accuracy those that are likely to respond to farnesyl transferase inhibitors and etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan AML patients, including elderly AML patients, who respond to a combination of one or more of , trastuzumab, and cisplatin. In one embodiment, the improvement includes using whole blood instead of the usual bone marrow sample, making the test more accurate, faster, less intrusive, less expensive and less painful. The method includes evaluating the expression ratio of the two genes (RASGRP1:APTX) in combination with corresponding thresholds, which provides sufficient precision for the prediction of response to combination therapy. A preferred embodiment is the combination therapy of tipifarnib (R1 15777,) combined with etoposide. Further, elderly AML patients identified as likely to respond to the combination of tipifarnib and etoposide had full recovery rates comparable to younger patients under optimal treatment conditions.